ACAD
33.72
+1.51
+4.69%
AEMD
2.25
-0.02
-0.88%
APRI
1.22
+0.02
+1.67%
ARNA
1.36
+0.06
+4.62%
ATEC
1.96
-0.04
-2.00%
CNAT
7.64
+0.1
+1.33%
CRXM
0.2
0.00
-2.20%
CYTX
1.1
+0.09
+8.91%
DXCM
74.89
-0.34
-0.45%
GNMK
12.55
+0.05
+0.40%
HALO
13.39
+0.11
+0.79%
ILMN
180.2
+4.91
+2.80%
INNV
0.095
-0.004
-3.965%
INO
6.53
+0.26
+4.15%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
105.12
+0.73
+0.70%
LPTN
2.93
0.00
0.00%
MBVX
2.01
+0.12
+6.35%
MEIP
1.56
-0.01
-0.64%
MNOV
5.43
-0.4
-6.86%
MRTX
4.4
+0.15
+3.53%
MSTX
0.138
+0.008
+6.2308%
NBIX
51.78
+0.68
+1.33%
NUVA
76.35
+1.33
+1.77%
ONCS
1.17
-0.03
-2.4917%
ONVO
2.73
+0.02
+0.74%
OREX
2.98
+0.09
+3.11%
OTIC
12.5
+0.15
+1.21%
QDEL
23.5
-0.06
-0.25%
RCPT
231.96
0.00
0.00%
RGLS
1.4
0.00
0.00%
RMD
70.74
+0.9
+1.29%
SPHS
2.61
+0.01
+0.38%
SRNE
1.75
-0.05
-2.78%
TROV
0.88
+0.052
+6.2832%
VICL
2.369
+0.109
+4.823%
VOLC
18
0.00
0.00%
ZGNX
10.6
-0.1
-0.93%
ACAD
33.72
+1.51
+4.69%
AEMD
2.25
-0.02
-0.88%
APRI
1.22
+0.02
+1.67%
ARNA
1.36
+0.06
+4.62%
ATEC
1.96
-0.04
-2.00%
CNAT
7.64
+0.1
+1.33%
CRXM
0.2
0.00
-2.20%
CYTX
1.1
+0.09
+8.91%
DXCM
74.89
-0.34
-0.45%
GNMK
12.55
+0.05
+0.40%
HALO
13.39
+0.11
+0.79%
ILMN
180.2
+4.91
+2.80%
INNV
0.095
-0.004
-3.965%
INO
6.53
+0.26
+4.15%
ISCO
1.65
-0.1
-5.71%
ISIS
57.56
0.00
0.00%
LGND
105.12
+0.73
+0.70%
LPTN
2.93
0.00
0.00%
MBVX
2.01
+0.12
+6.35%
MEIP
1.56
-0.01
-0.64%
MNOV
5.43
-0.4
-6.86%
MRTX
4.4
+0.15
+3.53%
MSTX
0.138
+0.008
+6.2308%
NBIX
51.78
+0.68
+1.33%
NUVA
76.35
+1.33
+1.77%
ONCS
1.17
-0.03
-2.4917%
ONVO
2.73
+0.02
+0.74%
OREX
2.98
+0.09
+3.11%
OTIC
12.5
+0.15
+1.21%
QDEL
23.5
-0.06
-0.25%
RCPT
231.96
0.00
0.00%
RGLS
1.4
0.00
0.00%
RMD
70.74
+0.9
+1.29%
SPHS
2.61
+0.01
+0.38%
SRNE
1.75
-0.05
-2.78%
TROV
0.88
+0.052
+6.2832%
VICL
2.369
+0.109
+4.823%
VOLC
18
0.00
0.00%
ZGNX
10.6
-0.1
-0.93%
Home » Archive by Category

Syndication

Sorrento Announces Pricing of Public Offering of Common Stock

April 13, 2017 – 5:58 am

SAN DIEGO, April 13, 2017 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”), an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, today announced the pricing of its public offering of 23,625,084 shares of its common stock at a price to the public of $2.00 per share. In addition, Sorrento has granted the underwriters an option exercisable, in whole or in part, in the sole discretion of the underwriters, to purchase up to 3,543,763 additional shares, for a period of up to 30 days. All of the shares will be offered and sold by Sorrento. Henry Ji, Ph.D., Sorrento’s President and Chief Executive Officer and a member of Sorrento’s board of directors, is purchasing shares in the offering.

Cantor Fitzgerald & Co. is acting as the lead book-running manager for the offering.  FBR Capital Markets & Co. is also acting as a joint book-running manager. Oppenheimer & Co. and Aegis Capital Corp. are acting as co-lead managers and Joseph Gunnar & Co., Rodman & Renshaw and Roth Capital Partners are acting as co-managers.

The public offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-199849) previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) on December 3, 2014.  The securities may be offered only by means of a prospectus.  A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, and when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by telephone at 212-829-7122, or by e-mail at prospectus@cantor.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Sorrento Therapeutics, Inc. 

Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento’s lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products. 

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the proposed underwritten public offering and other matters that are described in Sorrento’s most recent periodic reports filed with the SEC, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2016, as amended, and the preliminary prospectus supplement related to the proposed offering filed with the SEC on or about the date hereof, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

All other trademarks and trade names are the property of their respective owners.

© 2017 Sorrento Therapeutics, Inc.  All Rights Reserved.

 

SOURCE Sorrento Therapeutics, Inc.

Tocagen Announces Pricing of Initial Public Offering

April 13, 2017 – 4:30 am

SAN DIEGO, April 13, 2017 /PRNewswire/ — Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced the pricing of its initial public offering of 8,500,000 shares of common stock at a public offering price of $10.00 per share. The shares are expected to begin trading on the NASDAQ Global Select Market on April 13, 2017 under the ticker symbol “TOCA.” In addition, Tocagen has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock at the initial public offering price.

Leerink Partners LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint bookrunning managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 12, 2017. The offering will be made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110 or by telephone at (800) 808-7525, ext. 6132 or by email at syndicate@leerink.com; or from Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Tocagen

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. Tocagen is developing its lead product candidate, Toca 511 & Toca FC, initially for the treatment of recurrent high grade glioma, a disease with a significant unmet medical need. Tocagen has received grant support from leading brain cancer foundations, including Accelerate Brain Cancer Cure (ABC2), National Brain Tumor Society (NBTS), American Brain Tumor Association (ABTA), Musella Foundation and Voices Against Brain Cancer (VABC).

 

SOURCE Tocagen Inc.

Manager/Senior Manager, Quality Assurance – Heron Therapeutics – San Diego, CA

April 13, 2017 – 1:59 am

Review of executed production records and QC testing results to determine QA disposition decisions (API, excipients, drug product, drug/device combination final…From BioSpace.com – Thu, 13 Apr 2017 09:59:10 GMT – View all San Diego jobs

Senior Research Associate – NantKwest – San Diego, CA

April 13, 2017 – 12:15 am

MS with at least 1 year of work experience preferably in a biotechnology or pharmaceutical industry setting. NantKwest Inc., an innovative cell therapy company,…From NantKwest – Thu, 13 Apr 2017 08:15:03 GMT – View all San Diego jobs

Sr. Director, Biostatistics and Data Management – Intercept Pharmaceuticals – San Diego, CA

April 12, 2017 – 10:26 pm

Provide guidance into development and implementation of data management and statistical programming standards and ensures that the standards are followed;…From Intercept Pharmaceuticals – Thu, 13 Apr 2017 06:26:36 GMT – View all San Diego jobs

Sr. Medical Writer – Intercept Pharmaceuticals – San Diego, CA

April 12, 2017 – 10:26 pm

Bachelor’s degree in life sciences with 4-5 years or more direct biotechnology or pharmaceutical industry experience as a medical writer, or advanced scientific…
From Intercept Pharmaceuticals – Thu, 13 Apr 2017 06:26:36 GMT – View all San Diego jobs

Associate Director, Global Medical Communications – Intercept Pharmaceuticals – San Diego, CA

April 12, 2017 – 10:26 pm

Minimum 5 years of experience in the pharmaceutical or biotechnology industry required, to at least 3 years of medical communication/information experience….From Intercept Pharmaceuticals – Thu, 13 Apr 2017 06:26:36 GMT – View all San Diego jobs

Associate Director / Director Medical Writing (Publications) – Intercept Pharmaceuticals – San Diego, CA

April 12, 2017 – 10:26 pm

Bachelor’s degree in life sciences with 6-7 years or more direct biotechnology or pharmaceutical industry experience as a medical writer, or advanced scientific…
From Intercept Pharmaceuticals – Thu, 13 Apr 2017 06:26:33 GMT – View all San Diego jobs

Research Associate 1 – Bayside Solutions – San Diego, CA

April 12, 2017 – 10:01 pm

This is an opportunity to work for a great Biotechnology company that develops, manufactures and markets integrated systems for the analysis of genetic…From Bayside Solutions – Thu, 13 Apr 2017 06:01:27 GMT – View all San Diego jobs

Technical Operations Manager – BioPhase Solutions – San Diego, CA

April 12, 2017 – 9:47 pm

5-10 years’ relevant experience in Biotech, Pharmaceutical, or Contract Manufacturing organizations. The Technical Operations Manager works closely with…
From BioPhase Solutions – Thu, 13 Apr 2017 05:47:11 GMT – View all San Diego jobs